Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05853367 · ClinicalTrials.gov registry record · Phase 1

Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)

A Phase 1 study of Advanced Solid Tumors and Metastatic Solid Tumors, sponsored by Merck Sharp & Dohme.

Recruiting
Registry status
Phase 1
Development phase
178
Enrollment target
20
Study locations

NCT05853367 is a Phase 1 study of Advanced Solid Tumors and Metastatic Solid Tumors that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 178 participants, below the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (10% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05853367, a Phase 1 study of Advanced Solid Tumors and Metastatic Solid Tumors, is actively recruiting participants, sponsored by Merck Sharp & Dohme.

RECRUITING
Registry status
Phase 1
Development phase
178 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to assess the efficacy, safety, and tolerability of MK-0472 administered as monotherapy and in combination with pembrolizumab (MK-3475) or MK-1084 in participants with histologically or cytologically confirmed diagnosis of advanced/metastatic solid tumors.

Conditions Studied

Advanced Solid Tumors Metastatic Solid Tumors

Interventions

  • BIOLOGICAL Pembrolizumab
  • DRUG MK-1084
  • DRUG MK-0472

Study Locations (20)

Other

  • Rambam Health Care Campus ( Site 0304) - Haifa
  • Shaare Zedek Medical Center ( Site 0303) - Jerusalem
  • Rabin Medical Center ( Site 0301) - Petah Tikva
  • Sheba Medical Center ( Site 0300) - Ramat Gan
  • Sourasky Medical Center ( Site 0302) - Tel Aviv

Region M. de Santiago

  • Centro de Estudios Clínicos SAGA ( Site 0701) - Santiago
  • Fundacion Arturo Lopez Perez ( Site 0700) - Santiago
  • Centro de Investigacion Clinicadela Universidad Catolica ( Site 0703) - Santiago
  • Bradfordhill ( Site 0702) - Santiago

New Jersey

  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 0001) - Hackensack
  • Rutgers Cancer Institute of New Jersey ( Site 0005) - New Brunswick

Quebec

  • Centre Hospitalier de l'Université de Montréal-Unit for Innovative Therapies ( Site 0100) - Montreal
  • Jewish General Hospital ( Site 0104) - Montreal

Illinois

  • Northwestern Memorial Hospital ( Site 0002) - Chicago

Kentucky

  • The University of Louisville, James Graham Brown Cancer Center ( Site 0004) - Louisville

Ontario

  • Princess Margaret Cancer Centre ( Site 0101) - Toronto

Masovian Voivodeship

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 0401) - Warsaw

Trial Details

FieldValue
Enrollment Target 178 participants
Start Date 2023-07-06
Est. Completion 2028-02-12
Phase Phase 1

Sponsor

Merck Sharp & Dohme

558 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05853367

The ClinicalTrials.gov registry entry for NCT05853367 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 178 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (10% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Advanced Solid Tumors appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.

NCT05853367 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, Region M. de Santiago, New Jersey.

Frequently Asked Questions

What is clinical trial NCT05853367 about?

NCT05853367 is a clinical study titled "Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)". The purpose of this study is to assess the efficacy, safety, and tolerability of MK-0472 administered as monotherapy and in combination with pembrolizumab (MK-3475) or MK-1084 in participants with histologically or cytologically confirmed diagnosis of advanced/metastatic solid tumors.

What is the current status of trial NCT05853367?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 178 participants. The study started on 2023-07-06. Estimated completion is 2028-02-12.

What conditions does trial NCT05853367 study?

This clinical trial studies the following conditions: Advanced Solid Tumors, Metastatic Solid Tumors.

What interventions are being tested in trial NCT05853367?

The interventions under investigation include: Pembrolizumab (BIOLOGICAL), MK-1084 (DRUG), MK-0472 (DRUG).

Who is sponsoring clinical trial NCT05853367?

This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05853367 being conducted?

This trial has 20 study locations across Illinois, Kentucky, New Jersey, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

Metastatic Solid Tumors

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.